| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Workshop: Seizing Policy Opportunities for Life Extension and Overcoming Political Obstacles in 2026 | Led by Gennady Stolyarov II, Chairman, United States Transhumanist Party | |||||||||||||||||||||||||||
2 | Presented at Vitalist Bay - Thursday, May 14, 2026 | Policy Opportunities | Political Obstacles | ||||||||||||||||||||||||||
3 | Expanded Right to Try | ARPA-H Funding for Vitalist-Aligned Projects | Expedited FDA Approvals | Free Economic Zones / Freedom Cities | Potential Pro-Longevity Programs in Other Countries | Partisan Polarization | Cuts to NIH Funding | Anti-Vaccine / Anti-Science Sentiments | Unrelated Political Conflicts Stifling Longevity Research | ||||||||||||||||||||
4 | Example 1: | Montana Right to Try Act - SB 422 (2023) and SB 535 (2025) | FRONT Program (Functional Repair of Neocortical Tissue), Jean Hebert | Expanded Access granted to daraxonrasib, anti-pancreatic-cancer drug, on May 1, 2026, 2 days after FDA received the application. | Próspera / Infinita City | Russian $26 billion investment into "anti-aging vaccines" (really, a gene-therapy drug that would target the RAGE receptor) | Example 1: | Rise in left-wing opposition to transhumanism because of alleged association with Peter Thiel and Elon Musk (who have not self-identified as transhumanists) | New NIH grants for both Alzheimer's Disease and aging research reduced by about half | Delays, Eligibility Restrictions to Public Access to mRNA and Novavax Vaccines in 2025 | Cuts to Harvard labs (David Sinclair, George Church) in 2025 due to Trump Adminsitration's dispute with Ivy League universities (though most funding recovered by October 2025) | ||||||||||||||||||
5 | Example 2: | New Hampshire Expanded Right to Try Law (HB 701, 2025) - Propsed HB 1734, HB 1735 (2026) | PROSPR Program (Proactive Solutions for Prolonging Resilience), Andrew Brack | 49 FDA-approved cell and gene therapies as of April 23, 2026 | Immortalis / Neovia | Initiatives in Javier Milei's Argentina? | Example 2: | Reflexive Democratic opposition to New Hampshire Right to Try Laws | Hundreds of cancer-related research grants were terminated, including research into a novel treatment for glioblastoma using nanoparticles by Eden Tanner at the University of Mississippi | 22 mRNA vaccine research projects cancelled and defunded in 2025, no new mRNA-based projects allowed be initiated | Geopolitical conflicts (e.g., tensions with Russia over Ukraine and with China over Taiwan) preventing meaningful collaboration and exchange of ideas and research findings | ||||||||||||||||||
6 | Example 3: | Nevada Freedom to Try Medical Innovations Amendment (Potential 2026 Ballot Initiative) | PRINT Program (Personalized Regenerative Immunocompetent Nanotechnology Tissue), Ryan Spitler | FDA allowed the Investigational New Drug (IND) application of EVM14, an mRNA anti-cancer vaccine for non-small-cell lung cancer and head and neck cancer (March 2025), Phase I trials began in November 2025. | Viva City / Frontier Tower | China's booming longevity industry, considered a national priority by the government, with the support of Xi Jinping | Example 3: | Democrats in the House of Representatives largely opposed the Federal Right to Try Act of 2017, which passed the House by a vote of 267 to 149 on the second try, with most Democrats opposed. | National Instute of Aging cut funding for the Dog Aging Project in 2024. (The project has since been continued due to private funding.) | Bans on in vitro / lab-grown meat in 8 States: Alabama, Florida, Indiana, Mississippi, Montana, Nebraska, South Dakota, and Texas | February 2025 arrest and detention of Ksenia Petrova, researcher at Harvard Medical School, for entering the country with undeclared frog embryos. (She was released in January 2026 and is back at work.) | ||||||||||||||||||
7 | Example 4: | BoSS Program (BioStabilization Systems), Gloria Elliott | Additional Example? | ||||||||||||||||||||||||||
8 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
9 | Importance in Your View | 3 - Moderately Important | 4 - Quite Important | 4 - Quite Important | 1 - Only Slightly Important | 4 - Quite Important | 4 - Quite Important | 4 - Quite Important | 4 - Quite Important | 4 - Quite Important | |||||||||||||||||||
10 | Comments | ||||||||||||||||||||||||||||
11 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
12 | Importance in Your View | 4 - Quite Important | 3 - Moderately Important | 3 - Moderately Important | 1 - Only Slightly Important | 4 - Quite Important | | | | | |||||||||||||||||||
13 | Comments | ||||||||||||||||||||||||||||
14 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
15 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
16 | Comments | ||||||||||||||||||||||||||||
17 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
18 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
19 | Comments | ||||||||||||||||||||||||||||
20 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
21 | Matt Handzel | handzelmatthew@gmail.com | Importance in Your View | 3 - Moderately Important | | | | | 4 - Quite Important | | | | |||||||||||||||||
22 | Comments | Right to try may be double edged sword; i.e. bryan johnson looking super young and fit because of xyz therapy (and more people like him) would be positive. i imagine there could be some potentially negative outcomes and people may point to this and say that is dangerous | |||||||||||||||||||||||||||
23 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
24 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
25 | Comments | ||||||||||||||||||||||||||||
26 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
27 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
28 | Comments | ||||||||||||||||||||||||||||
29 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
30 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
31 | Comments | ||||||||||||||||||||||||||||
32 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
33 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
34 | Comments | ||||||||||||||||||||||||||||
35 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
36 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
37 | Comments | ||||||||||||||||||||||||||||
38 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
39 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
40 | Comments | ||||||||||||||||||||||||||||
41 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
42 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
43 | Comments | ||||||||||||||||||||||||||||
44 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
45 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
46 | Comments | ||||||||||||||||||||||||||||
47 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
48 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
49 | Comments | ||||||||||||||||||||||||||||
50 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
51 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
52 | Comments | ||||||||||||||||||||||||||||
53 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
54 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
55 | Comments | ||||||||||||||||||||||||||||
56 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
57 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
58 | Comments | ||||||||||||||||||||||||||||
59 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
60 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
61 | Comments | ||||||||||||||||||||||||||||
62 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
63 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
64 | Comments | ||||||||||||||||||||||||||||
65 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
66 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
67 | Comments | ||||||||||||||||||||||||||||
68 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
69 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
70 | Comments | ||||||||||||||||||||||||||||
71 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
72 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
73 | Comments | ||||||||||||||||||||||||||||
74 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
75 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
76 | Comments | ||||||||||||||||||||||||||||
77 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
78 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
79 | Comments | ||||||||||||||||||||||||||||
80 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
81 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
82 | Comments | ||||||||||||||||||||||||||||
83 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
84 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
85 | Comments | ||||||||||||||||||||||||||||
86 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
87 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
88 | Comments | ||||||||||||||||||||||||||||
89 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
90 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
91 | Comments | ||||||||||||||||||||||||||||
92 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
93 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
94 | Comments | ||||||||||||||||||||||||||||
95 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
96 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
97 | Comments | ||||||||||||||||||||||||||||
98 | Name | E-mail Address | Organization | Your Outlook | Your Outlook | ||||||||||||||||||||||||
99 | Importance in Your View | | | | | | | | | | |||||||||||||||||||
100 | Comments | ||||||||||||||||||||||||||||